Lithium a continuing story in the treatment of bipolar disorder

Size: px
Start display at page:

Download "Lithium a continuing story in the treatment of bipolar disorder"

Transcription

1 Acta Psychiatr Scand 2005: 111 (Suppl. 426): 7 12 All rights reserved Copyright ª Blackwell Munksgaard 2005 ACTA PSYCHIATRICA SCANDINAVICA Lithium a continuing story in the treatment of bipolar disorder Carney SM, Goodwin GM. Lithium a continuing story in the treatment of bipolar disorder. Acta Psychiatr Scand 2005: 111 (Suppl. 426): ª Blackwell Munksgaard Objective: To review the literature on the use of lithium in the treatment of bipolar disorder and highlight the evidence base supporting its efficacy and safety. Method: A selective literature review. Results: Lithium is widely believed to be effective against acute mania, acute bipolar depression and in relapse prevention to either mania or depression. In fact, the data supporting efficacy in acute treatment are less impressive than is often claimed, whereas for relapse prevention and suicide prevention no other agent has comparable depth of support. Lithium is best described as the bench mark treatment for bipolar disorder, rather than the gold standard, because only a minority of patients show major clinical benefit. There is a developing need for further trials against new alternatives and in combination studies. Conclusion: Lithium has a continuing important role in the clinical management of bipolar disorder. Its under-utilization in North America reflects opinion rather than evidence and the demonstrated anti-suicide effects should help to reignite interest in its use. S. M. Carney, G. M. Goodwin University Department of Psychiatry, Warnford Hospital, Oxford, UK Key words: lithium; bipolar disorder; evidence-based medicine; trials; mood stabilizer Guy Goodwin, University Department of Psychiatry, Warnford Hospital, Oxford OX3 7JX, UK. guy.goodwin@psych.ox.ac.uk Introduction Lithium is the archetypal mood stabilizer. First used in psychiatry in the late 1940Õs, it rapidly became the standard treatment for relapse prevention in bipolar disorder (1). The last decade, however, has seen a dramatic reduction in its use, especially in North America. This has largely been because of concerns about its effectiveness, adherence to treatment and the risk of rebound mania following abrupt discontinuation (2 5). The promotion of newer anticonvulsants, starting with valproate, as both effective and easier to use has resulted in many clinicians discarding lithium. However, there is a substantial evidence base supporting the use of lithium both in the treatment of mania and in the prevention of relapse (6 8). Recent maintenance studies examining the relapse prevention credentials of anticonvulsants have, almost inadvertently, contributed substantial additional data in support of lithium (7). It may be premature to say so, and perhaps over optimistic, but we anticipate a renaissance of lithium s fortunes particularly in North America based on this new data. We will explain why, giving emphasis to papers that synthesize the evidence base as reviews and meta-analyses and consider directions for future research. Aims of the study The following article reviews the evidence-base that supports the use of lithium in the treatment of bipolar disorder and critically examines its credentials as a mood stabilizer. Material and methods In this paper we provide the results of a selective review of the evidence as regards the use of lithium in the treatment of bipolar disorder. The authors drew on articles known to them and performed additional searches of the literature as deemed appropriate. 7

2 Carney and Goodwin Results Evidence-base for the treatment of mania Lithium was first claimed to be effective in bipolar disorder on the basis of uncontrolled open treatment of acute mania (9). There is now convincing randomized evidence to support the use of lithium in mania (10). One systematic review describing the results from a single randomized controlled trial (RCT) found that more patients with bipolar type 1 disorder responded after 3 4 weeks with lithium compared with placebo (8). Compared with valproate, a Cochrane review of three RCT found no difference in the proportion of people responding over 3 6 weeks (11). In the largest head-to-head randomized comparison with chlorpromazine, lithium was less effective in the most active patients (12). Nevertheless, it was slightly superior to chlorpromazine in other smaller studies, demonstrated similar efficacy to haloperidol and olanzapine but was inferior to risperidone (8, 13). The choice of first-line agent for the treatment of mania remains controversial. The US clinical guidelines have consistently advocated the use of a mood-stabilizer alone for the treatment of mania or hypomania, reserving adjunctive use of antipsychotics for the most severe presentations (14). This is clearly at odds with the near universal use of antipsychotics to treat severe mania revealed by surveys in both the USA and Europe (15). In recognition of this data and the emerging support for the use of atypical antipsychotics in mania from well conducted placebo-controlled trials, the British Association for Psychopharmacology recommended initial oral administration of an antipsychotic or valproate because of their rapid anti-manic effect (16). The UK guidelines reserve short-term lithium treatment as an option for patients who are less ill and less likely to be metabolically compromised. When employed as an anti-manic agent, lithium levels of up to 1.4 mmol/l are commonly recommended in the acute phase. Evidence-base for the treatment of bipolar depression Lithium is usually described as effective in acute bipolar depression on the basis of a number of very small trials conducted early in its adoption as a treatment for bipolar disorder (17). Furthermore, there is a very pervasive consensus view that the first step in managing bipolar depression should be to initiate or ÔoptimizeÕ treatment with a mood stabilizer, usually lithium and the second should be to combine an antidepressant with the mood stabilizer (14, 18 20). On the basis of these recommendations, one might expect the evidence for lithium s efficacy as a single treatment or when combined with another agent to be convincing. Unfortunately, scrutiny of the actual trials quickly reveals their inadequacy (21). Obviously the absence of evidence is not evidence of an absence of effect, and the effects on relapse prevention and suicide favour some action against depression (see below), but it is ironic that lithium is so confidently advocated as a treatment for acute depression on so slender an evidence base. Evidence-base for relapse prevention The most recent systematic review examining the long-term effects of lithium identified five placebocontrolled randomized trials which had included only bipolar patients (7): 770 participants were followed either until relapse or for between 11 months and 4 years. Lithium levels were maintained between 0.5 and 1.4 mmol/l. Three of the included RCTs also examined anticonvulsants (divalproex and lamotrigine): these studies were only reported or published in the last 4 years (22 24). Relapse was typically defined as requiring clinical intervention (initiation of a new treatment or admission to hospital). Taking account of statistical heterogeneity, meta-analysis found that lithium compared with placebo, reduces the risk of relapse by about one-third (risk ratio (RR) ¼ 0.65, 95% CI: 0.50, 0.84) (see Fig. 1). The average risk Fig. 1. Randomized, placebo-controlled trials assessing the effectiveness of lithium for the prevention of any relapse in bipolar disorder patients (reproduced with permission from the American Journal of Psychiatry, Copyright American Psychiatric Association). 8

3 Lithium in the treatment of bipolar disorder of relapse in the placebo group was 60% compared with 40% on lithium suggesting that five patients need to be treated with lithium to prevent one additional relapse within 2 years. Examining the character of the experienced relapses, suggests that lithium is more effective in the prevention of mania (RR ¼ 0.62; 95% CI: 0.40, 0.95) (7) (see Fig. 2) than depression (RR ¼ 0.85, 95% CI ¼ 0.66, 1.11)(25) (see Fig. 3). The adverse effect profile did not appear to be too burdensome with 14% (fixed effects RR ¼ 0.86; 95% CI: 0.80, 0.93) fewer participants on lithium withdrawing prematurely from the trial. Hypothyroidism, nausea, somnolence and diarrhoea occurred more commonly among those treated with lithium. Side-effects with lithium are dose related and the RCTs have aimed for levels >0.8 mmol/l, which are higher than usually achieved in clinical practice because of the trade-off between effectiveness and tolerability. One study that re-assigned patients to high or low lithium levels had an interesting outcome (3). Patients tolerating high levels who were re-assigned to lower levels tended to show an excess of relapse. By contrast there was no benefit from re-assigning patients with low prevailing lithium levels to higher doses. Accordingly, the highest well-tolerated dose should be recommended for the long term to optimize adherence to treatment. Poor adherence is a contraindication to lithium because abrupt discontinuation of treatment increases the short-term risk of relapse (26, 27). The RCTs have also allowed some comparison between lithium and the anticonvulsants: valproate, carbamazepine and lamotrogine. Valproate (usually as semi-sodium valproate) is the most commonly prescribed mood-stabilizer although there is only one RCT examining comparative effectiveness in the maintenance phase (28). For the systematic review including this RCT, relapse was the primary outcome measure. There was no statistically significant difference between the two medicines by 12 months but there was a trend in favour of divalproex (RR 0.8; 95% CI 0.5, 1.2). Secondary endpoints in the RCT suggested that divalproex may be superior to lithium in effecting longer duration of successful prophylaxis and better depressive symptom and Global Assessment Scale scores (22). The trial was an important landmark the first large maintenance study in bipolar disorder for 20 years and has informed subsequent studies as much by its failings (recruitment of non-severe patients, admission to hospital as the sole primary endpoint), as by its strengths. The side-effect profile favoured divalproex with more participants on lithium experiencing polyuria, thirst, tachycardia, akathisia and dry eyes while more participants taking divalproex felt sedated or experienced tinnitus. Similarly, no statistically significant differences were identified when the effectiveness of lithium was compared with carbamazepine in a systematic review which included the MAP study (29). Fig. 2. Randomized, placebo-controlled trials assessing the effectiveness of lithium for the prevention of manic relapse in bipolar disorder patients (reproduced with permission from the American Journal of Psychiatry, Copyright American Psychiatric Association). Fig. 3. Randomized, placebo-controlled trials assessing the effectiveness of lithium for the prevention of depressive relapse in bipolar disorder patients (reproduced with permission from the American Journal of Psychiatry, Copyright American Psychiatric Association). 9

4 Carney and Goodwin However, a subsequent well conducted trial in patients starting maintenance treatment for the first time suggested that lithium was superior to carbamazepine (30). Two studies of lamotrigine showed no overall difference (23, 31) but see Calabrese (this issue) for a discussion of the differential effect of lithium (more effective against mania) and lamotrigine (more effective against depression). Suicide prevention An estimated 6% of individuals with affective disorders including those diagnosed with bipolar disorder commit suicide (32). Combining the results from follow-up studies conducted throughout the last century suggests that patients with bipolar disorder have a 15 times greater than expected risk of suicide (33). Furthermore, between a quarter and a half of patients with bipolar disorder attempt suicide (34). The RCT have been underpowered to assess whether mood-stabilizers including lithium are effective in preventing suicide and deliberate self harm. However, in a systematic review of all relevant trials reporting mortality and suicide, more of the lithium-treated participants survived than those in the comparison groups (35). There is also consistent evidence from nonrandomized studies that lithium not only reduces the risk of suicide attempts but also completed suicide (36). Meta-analysis of the results of 33 observational studies investigating the effectiveness of lithium suggests a 13-fold reduction among those receiving long-term treatment (37). A further retrospective cohort study with a population-based sample suggests that lithium may be more effective in reducing suicidal acts and behaviours than divalproex (38). Even adjusting for a number risk factors for suicide (age, sex, health plan, year of diagnosis, comorbid medical and psychiatric conditions, and concurrent use of other psychotropic drugs) the risk of completed suicide was 2.7 (95% CI: ) times higher among those treated with divalproex compared with lithium. The possibility of Ôconfounding by indicationõ cannot be overlooked and may have resulted in the most stable patients receiving lithium and the more unwell receiving divalproex (39). There was a similar trend when lithium was compared with carbamazepine although far fewer patients were taking this mood stabilizer. The latter result is consistent with the subgroup analyses from the MAP RCT suggesting that lithium is more effective in preventing both suicide attempts and acts than carbamazepine (40). Discussion Lithium has claims to meet the most stringent criteria for a mood stabilizer (17). It is widely believed to be effective against acute mania, acute bipolar depression and in relapse prevention to either mania or depression. In fact the data for acute treatment is less impressive than is often claimed, but for relapse prevention and suicide prevention no other agent has comparably convincing data from multiple trials. Lithium is sometimes called the gold standard treatment for bipolar disorder. In fact, it would be best described as the bench mark treatment. It is the treatment against which other medicines should be measured in headto-head comparison. There is an urgent need for large simple RCT investigating the effectiveness of lithium alone and in combination compared with other agents in the prevention of not only relapse but also deliberate self-harm and suicide. Improving concordance with treatment regimes remains one of the greatest clinical challenges and future research must also evaluate strategies to improve quality of life and functioning. There are two major relapse prevention studies currently underway, Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) and Bipolar Affective Disorder Lithium/Anticonvulsant Comparative Evaluation (BALANCE). The STEP-BD is a US, multicentre, longitudinal study, which provides a platform for a variety of clinical trials and other studies (41). The randomized treatment opportunities include a 2-year double-blind comparison of any mood-stabilizer and placebo compared with divalproex and lithium for patients who have become manic on either lithium or divalproex alone. Outcomes of interest include recovery, time to event, drop-out, care utilization, time in remission and functional impairment. The BALANCE is a multicentre, UK and US, randomized trial comparing lithium, divalproex and lithium and divalproex in combination (42). The pilot study and start-up phase have identified a number of pragmatic refinements to promote recruitment and follow-up including: the dropping of masking (blinding) of participants and clinicians, the introduction of postal medication delivery and fewer follow-up appointments (43). The study plans to randomize as many participants as possible before the end of 2005 and will assess whether the combination treatment arm is more effective in preventing hospital admission over a 2-year period than either monotherapy. To conclude the renewed research interest in lithium not just as Ôtreatment-as-usualÕ but also as a 10

5 Lithium in the treatment of bipolar disorder component of combination therapy suggests that lithium will continue to play an important role in clinical practice. We hope its much reduced role in North America will be followed by a recovery of interest, particularly because of the apparent effectiveness in preventing suicide and an improved appreciation of the need for evidence rather than opinion in shaping clinical practice. Acknowledgements This article has been supported by an unrestricted educational grant from Sanofi-Aventis. The authors would like to thank Professor John Geddes for providing data from the systematic review of long-term lithium therapy for bipolar disorder and the American Journal of Psychiatry for granting permission to reproduce the forest plots. Declaration of interest GMG is in receipt of grant support from Sanofi-Aventis for BALANCE and has advised Solvay pharmaceuticals on two occasions in the last 5 years. SC is a seconded advisor to the Department of Health (England) for postgraduate medical education and has also received an honorarium from Lundbeck for teaching their employees the principles of evidence-based practice. References 1. Coppen A. 50 years of lithium treatment of mood disorders. Bipolar Disord 1999;1: Jamison KR, Akiskal HS. Medication compliance in patients with bipolar disorder. Psychiatr Clin North Am 1983;6: Perlis RH, Sachs GS, Lafer B et al. Effect of abrupt change from standard to low serum levels of lithium: a reanalysis of double-blind lithium maintenance data. Am J Psychiatry 2002;159: Moncrie J. Lithium: evidence reconsidered. Br J Psychiatry 1997;171: Gelenberg AJ, Kane JM, Keller MB et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989;321: Burgess S, Geddes J, Hawton K, Townsend E, Jamison K, Goodwin G. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev 2001; Issue Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004;161: Poolsup N, Li Wan PA, De Oliveira IR. Systematic overview of lithium treatment in acute mania. J Clin Pharm Ther 2000;25: Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949;2: Geddes J. Bipolar disorder. Clin Evid 2004;11: Macritchie K, Geddes JR, Scott J, Haslam D, De Lima M, Goodwin G. Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev 2003; Issue Prien RF, Caey EM Jr, Klett CJ. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry 1972;26: Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int Clin Psychopharmacol 1999;14: Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP. The expert consensus guideline series: medication treatment of bipolar disorder Postgrad Med 2000; Special Report: Cookson J. Use of antipsychotic drugs and lithium in mania. Br J Psychiatry Suppl 2001;41:S148 S Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003;17: Bauer MS, Mitchner L. What is a Ômood stabilizer? An evidence-based response. Am J Psychiatry 2004;161: American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159: Bauer MS, Callahan AM, Jampala C et al. Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs. J Clin Psychiatry 1999;60: Suppes T, Swann AC, Dennehy EB et al. Texas Medication Algorithm Project: development and feasibility testing of a treatment algorithm for patients with bipolar disorder. J Clin Psychiatry 2001;62: Bhagwagar Z, Goodwin GM. The role of lithium in the treatment of bipolar depression. Clin Neurosc Res 2004;2: Bowden CL, Calabrese JR, Mcelroy SL et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000;57: Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60: Bowden CL, Ghaemi SN, Gyulai L et al. Lamotrigine delays mood episodes in recently depressed bipolar I patients, Annual Meeting New Research Program and Abstracts. Washington DC: American Psychiatric Association, Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Correction. Am J Psychiatry 2004;161: Goodwin GM. Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder. Br J Psychiatry 1994;164: Johnson RE, Mcfarland BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry 1996;153: Macritchie KA, Geddes JR, Scott J, Haslam DR, Goodwin GM. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2001; Issue Davis JM, Janicak PG, Hogan DM. Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis. Acta Psychiatr Scand 1999;100: Hartong EG, Moleman P, Hoogduin CA, Broekman TG, Nolen WA. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 2003;64:

6 Carney and Goodwin 31. Calabrese JR, Bowden CL, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64: Inskip HM, Harris EC, Barraclough B. Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. Br J Psychiatry 1998;172: Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997; 170: Jamison KR. Suicide and bipolar disorder. J Clin Psychiatry 2000;61(suppl. 9): Cipriani A, Wilder H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behaviour and all-cause mortality in patients with mood disorders: a systematic review of randomised trials. Am J Psychiatry, 2005 (In Press). 36. Dunner DL. Correlates of suicidal behavior and lithium treatment in bipolar disorder. J Clin Psychiatry 2004; 65(suppl. 10): Baldessarini RJ, Tondo L, Hennen J. Treating the suicidal patient with bipolar disorder. Reducing suicide risk with lithium. Ann NY Acad Sci 2001;932: Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003;290: Walker AM. Confounding by indication. Epidemiology 1996;7: Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology 2000; 42(suppl. 1): Sachs GS, Thase ME, Otto MW et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2003;53: Geddes J, Goodwin G. Bipolar disorder: clinical uncertainty, evidence-based medicine and large-scale randomised trials. Br J Psychiatry 2001;41(suppl.):S191 S Rendell JM, Juszczak E, Hainsworth J et al. Developing the BALANCE trial the role of the pilot study and start-up phase. Bipolar Disord 2004;6:

Suicide in Bipolar Disorder. Julie Anderson, MD Oregon State Hospital Psychiatrist OHSU Assistant Professor September 25, 2012

Suicide in Bipolar Disorder. Julie Anderson, MD Oregon State Hospital Psychiatrist OHSU Assistant Professor September 25, 2012 Suicide in Bipolar Disorder Julie Anderson, MD Oregon State Hospital Psychiatrist OHSU Assistant Professor September 25, 2012 Disclosure Statement I have no significant financial relationships to disclose...

More information

Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents

Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder,

More information

Improving the Recognition and Treatment of Bipolar Depression

Improving the Recognition and Treatment of Bipolar Depression Handout for the Neuroscience Education Institute (NEI) online activity: Improving the Recognition and Treatment of Bipolar Depression Learning Objectives Apply evidence-based tools that aid in differentiating

More information

PAPEL DE LA PSICOTERAPIA EN EL TRATAMIENTO DEL TRASTORNO BIPOLAR

PAPEL DE LA PSICOTERAPIA EN EL TRATAMIENTO DEL TRASTORNO BIPOLAR PAPEL DE LA PSICOTERAPIA EN EL TRATAMIENTO DEL TRASTORNO BIPOLAR Dr. Francesc Colom PsyD, MSc, PhD Bipolar Disorders Program IDIBAPS- CIBERSAM -Hospital Clínic Barcelona, University of Barcelona Centro

More information

Conjoint Professor Brian Draper

Conjoint Professor Brian Draper Chronic Serious Mental Illness and Dementia Optimising Quality Care Psychiatry Conjoint Professor Brian Draper Academic Dept. for Old Age Psychiatry, Prince of Wales Hospital, Randwick Cognitive Course

More information

Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care

Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care Issue date: July 2006 Bipolar disorder The management of bipolar disorder in adults, children and adolescents, in primary and secondary care NICE clinical guideline 38 Developed by the National Collaborating

More information

Much of our current conceptual

Much of our current conceptual DIAGNOSTIC BOUNDARIES BETWEEN BIPOLAR DISORDER AND SCHIZOPHRENIA: IMPLICATIONS FOR PHARMACOLOGIC INTERVENTION * Stephen M. Strakowski, MD ABSTRACT Schizophrenia and bipolar disorder are distinguished primarily

More information

Bipolar Disorder. Mania is the word that describes the activated phase of bipolar disorder. The symptoms of mania may include:

Bipolar Disorder. Mania is the word that describes the activated phase of bipolar disorder. The symptoms of mania may include: Bipolar Disorder What is bipolar disorder? Bipolar disorder, or manic depression, is a medical illness that causes extreme shifts in mood, energy, and functioning. These changes may be subtle or dramatic

More information

Treatment of Bipolar Disorders with Second Generation Antipsychotic Medications

Treatment of Bipolar Disorders with Second Generation Antipsychotic Medications Neuroendocrinology Letters ISSN 0172-780X Vol. 26, Supplement 1, August 2005 Treatment of Bipolar Disorders with Second Generation Antipsychotic Medications Marek Jarema Ljubomir Hotujac E. Timucin Oral

More information

Published 09 September 2013 1. 09 August 2013

Published 09 September 2013 1. 09 August 2013 aripiprazole 5mg, 10mg, 15mg, 30mg tablets, 10mg, 15mg orodispersible tablets, 1mg/mL oral solution (Abilify ) SMC No. (891/13) Otsuka Pharmaceutical (UK) Ltd 09 August 2013 The Scottish Medicines Consortium

More information

Medications for bipolar disorder

Medications for bipolar disorder Medications for bipolar disorder Findings from Australian National Survey of Mental Health and Wellbeing (Mitchell et al, 2004) In 12 months, only one-third saw a mental health professional 40% received

More information

STABLE. STAndards for BipoLar Excellence. A Performance Measurement & Quality Improvement Program PERFORMANCE MEASURES

STABLE. STAndards for BipoLar Excellence. A Performance Measurement & Quality Improvement Program PERFORMANCE MEASURES STABLE STAndards for BipoLar Excellence A Performance Measurement & Quality Improvement Program PERFORMANCE MEASURES Depression: Screening for bipolar mania/hypomania prior to treatment for depression

More information

This continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC.

This continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC. This continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC. Indiana University School of Medicine and CME Outfitters, LLC, gratefully acknowledge

More information

Available online through www.ijrap.net

Available online through www.ijrap.net Review Article Available online through www.ijrap.net BIPOLAR DISORDER: A REVIEW Pathan Dilnawaz N*, Ziyaurrahaman A.R, Bhise K.S. M.C.E.Society s Allana College of Pharmacy, Azam Campus, Pune, Maharastra,

More information

Pharmacologyonline 1: 78-87 (2005) DIAGNOSIS AND MANAGEMENT OF BIPOLAR DISORDER: RECENT DEVELOPMENTS AND CURRENT CONTROVERSIES

Pharmacologyonline 1: 78-87 (2005) DIAGNOSIS AND MANAGEMENT OF BIPOLAR DISORDER: RECENT DEVELOPMENTS AND CURRENT CONTROVERSIES DIAGNOSIS AND MANAGEMENT OF BIPOLAR DISORDER: RECENT DEVELOPMENTS AND CURRENT CONTROVERSIES Mario Department of Psychiatry, University of Naples SUN, Italy 78 Bipolar disorder is one of the mental disorders

More information

CLINICIAN INTERVIEW COMPLEXITIES OF BIPOLAR DISORDER. Interview with Charles B. Nemeroff, MD, PhD

CLINICIAN INTERVIEW COMPLEXITIES OF BIPOLAR DISORDER. Interview with Charles B. Nemeroff, MD, PhD COMPLEXITIES OF BIPOLAR DISORDER Interview with Charles B. Nemeroff, MD, PhD Dr Nemeroff is the Reunette W. Harris Professor and Chairman of the Department of Psychiatry and Behavioral Sciences at Emory

More information

Serious Mental Illness: Symptoms, Treatment and Causes of Relapse

Serious Mental Illness: Symptoms, Treatment and Causes of Relapse Serious Mental Illness: Symptoms, Treatment and Causes of Relapse Bipolar Disorder, Schizophrenia and Schizoaffective Disorder Symptoms and Prevalence of Bipolar Disorder Bipolar disorder, formerly known

More information

CLINICAL PRACTICE GUIDELINES Treatment of Schizophrenia

CLINICAL PRACTICE GUIDELINES Treatment of Schizophrenia CLINICAL PRACTICE GUIDELINES Treatment of Schizophrenia V. Service Delivery Service Delivery and the Treatment System General Principles 1. All patients should have access to a comprehensive continuum

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 26 April 2001 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON CLINICAL

More information

Advancing the pharmacological treatment of bipolar depression

Advancing the pharmacological treatment of bipolar depression Frangou Advances in Psychiatric Treatment (2005), vol. 11, 28 37 Advancing the pharmacological treatment of bipolar depression Sophia Frangou Abstract Bipolar disorder is a recurring, often chronic, illness

More information

Background. Population/Intervention(s)/Comparison/Outcome(s) (PICO) List of the systematic reviews identified by the search process

Background. Population/Intervention(s)/Comparison/Outcome(s) (PICO) List of the systematic reviews identified by the search process updated 2012 Treatment of alcohol withdrawal delirium Q3: In the treatment of alcohol withdrawal delirium, are benzodiazepines or antipsychotics safe and effective when compared to a placebo/appropriate

More information

Background. Population/Intervention(s)/Comparator/Outcome(s) (PICO)

Background. Population/Intervention(s)/Comparator/Outcome(s) (PICO) updated 2012 Role of anticholinergic medications in patients requiring long-term antipsychotic treatment for psychotic disorders Q6: In individuals with psychotic disorders (including schizophrenia) who

More information

BIPOLAR DISORDER A GUIDE FOR INDIVIDUALS AND FAMILIES FOR THE TREATMENT OF BIPOLAR DISORDER IN ADULTS

BIPOLAR DISORDER A GUIDE FOR INDIVIDUALS AND FAMILIES FOR THE TREATMENT OF BIPOLAR DISORDER IN ADULTS BIPOLAR DISORDER A GUIDE FOR INDIVIDUALS AND FAMILIES FOR THE TREATMENT OF BIPOLAR DISORDER IN ADULTS A publication of the Massachusetts Department of Mental Health and the Massachusetts Division of Medical

More information

Managing depression after stroke. Presented by Maree Hackett

Managing depression after stroke. Presented by Maree Hackett Managing depression after stroke Presented by Maree Hackett After stroke Physical changes We can see these Depression Emotionalism Anxiety Confusion Communication problems What is depression? Category

More information

Nalmefene for reducing alcohol consumption in people with alcohol dependence

Nalmefene for reducing alcohol consumption in people with alcohol dependence Nalmefene for reducing alcohol consumption in people with alcohol dependence Issued: November 2014 guidance.nice.org.uk/ta325 NICE has accredited the process used by the Centre for Health Technology Evaluation

More information

Bipolar disorder GUIDELINE

Bipolar disorder GUIDELINE Bipolar disorder F Colin 1. Introduction Bipolar disorder (BD) presents in different phases over time and is often complicated by comorbid conditions such as substance-use disorders and anxiety disorders.

More information

Diagnostic Boundaries of Bipolar Disorders. Terence A. Ketter, M.D.

Diagnostic Boundaries of Bipolar Disorders. Terence A. Ketter, M.D. Diagnostic Boundaries of Bipolar Disorders Terence A. Ketter, M.D. Disclosure Information Research Support / Consultant / Speaker Abbott Laboratories, Inc. AstraZeneca Pharmaceuticals LP Bristol Myers

More information

Bipolar Disorder. MOH Clinical Practice Guidelines 5/2011. Singapore Medical Association. Academy of Medicine, Singapore

Bipolar Disorder. MOH Clinical Practice Guidelines 5/2011. Singapore Medical Association. Academy of Medicine, Singapore Bipolar Disorder MOH Clinical Practice Guidelines 5/2011 College of Family Physicians, Singapore Academy of Medicine, Singapore Singapore Medical Association November 2011 Levels of evidence and grades

More information

Recognizing and Treating Bipolar Disorder

Recognizing and Treating Bipolar Disorder Clinical Review Article Recognizing and Treating Bipolar Disorder William R. Marchand, MD All physicians need to be familiar with the diagnosis and treatment of mood disorders. Fifty percent of all depressive

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (update) 1.1

More information

MOH CLINICAL PRACTICE GUIDELINES 6/2011 DEPRESSION

MOH CLINICAL PRACTICE GUIDELINES 6/2011 DEPRESSION MOH CLINICAL PRACTICE GUIDELINES 6/2011 DEPRESSION Executive summary of recommendations Details of recommendations can be found in the main text at the pages indicated. Clinical evaluation D The basic

More information

Medical marijuana for pain and anxiety: A primer for methadone physicians. Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015

Medical marijuana for pain and anxiety: A primer for methadone physicians. Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015 Medical marijuana for pain and anxiety: A primer for methadone physicians Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015 Conflict of interest statement No conflict of interest to

More information

Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder

Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Bipolar Disorder

More information

Ways to support the person with bipolar disorder

Ways to support the person with bipolar disorder Ways to support the person with bipolar disorder People differ in what help they need and want from caregivers. Caregivers differ in how involved they are in providing support. Finding ways to provide

More information

Major Depressive Disorder (MDD) Guideline Diagnostic Nomenclature for Clinical Depressive Conditions

Major Depressive Disorder (MDD) Guideline Diagnostic Nomenclature for Clinical Depressive Conditions Major Depressive Disorder Major Depressive Disorder (MDD) Guideline Diagnostic omenclature for Clinical Depressive Conditions Conditions Diagnostic Criteria Duration Major Depression 5 of the following

More information

Q4: Are acamprosate, disulfiram and naltrexone safe and effective in preventing relapse in alcohol dependence in nonspecialized health care settings?

Q4: Are acamprosate, disulfiram and naltrexone safe and effective in preventing relapse in alcohol dependence in nonspecialized health care settings? updated 2012 Preventing relapse in alcohol dependent patients Q4: Are acamprosate, disulfiram and naltrexone safe and effective in preventing relapse in alcohol dependence in nonspecialized health care

More information

Clinical Recommendations for Treatment of Bipolar Disorder for Hong Kong 2013

Clinical Recommendations for Treatment of Bipolar Disorder for Hong Kong 2013 Clinical Recommendations for Treatment of Bipolar Disorder for Hong Kong 2013 Version: March 2013 Objectives of Treatment Rapid control of symptoms especially agitation, impulsivity, aggression, suicidality

More information

Long-term worsening of bipolar disorder related with frequency of antidepressant exposure

Long-term worsening of bipolar disorder related with frequency of antidepressant exposure ANNALS OF CLINICAL PSYCHIATRY 2011;23(3):186-192 RESEARCH ARTICLE Long-term worsening of bipolar disorder related with frequency of antidepressant exposure Sergio A. Strejilevich, MD Bipolar Disorders

More information

Bipolar Disorder at work. Dr Micheline Tremblay & Fiona Cooper

Bipolar Disorder at work. Dr Micheline Tremblay & Fiona Cooper Bipolar Disorder at work Dr Micheline Tremblay & Fiona Cooper Aims and Objectives Recognising key symptoms of Bipolar Disorder. To identify why bipolar affects people in the workplace Symptoms Comorbidity

More information

Lithium and long-term prophylactic treatment

Lithium and long-term prophylactic treatment Lithium and long-term prophylactic treatment 5 LITHIUM 5.1 What is lithium? 102 5.2 How was lithium discovered? 102 5.3 How does lithium work? 102 5.4 How effective is lithium? 102 5.5 What are the indications

More information

DSM 5 AND DISRUPTIVE MOOD DYSREGULATION DISORDER Gail Fernandez, M.D.

DSM 5 AND DISRUPTIVE MOOD DYSREGULATION DISORDER Gail Fernandez, M.D. DSM 5 AND DISRUPTIVE MOOD DYSREGULATION DISORDER Gail Fernandez, M.D. GOALS Learn DSM 5 criteria for DMDD Understand the theoretical background of DMDD Discuss background, pathophysiology and treatment

More information

There are four groups of medications most likely to be used for depression: Antidepressants Antipsychotics Mood stabilisers Augmenting agents.

There are four groups of medications most likely to be used for depression: Antidepressants Antipsychotics Mood stabilisers Augmenting agents. What this fact sheet covers: Physical treatments (medication, ECT and TMS) Psychological treatments Self-help & alternative therapies Key points to remember Where to get more information. Introduction

More information

A Manic Episode is defined by a distinct period during which there is an abnormally and persistently elevated, expansive, or irritable mood.

A Manic Episode is defined by a distinct period during which there is an abnormally and persistently elevated, expansive, or irritable mood. Bipolar disorder Bipolar (manic-depressive illness) is a recurrent mode disorder. The patient may feel stable at baseline level but experience recurrent shifts to an emotional high (mania or hypomania)

More information

Management of bipolar disorder: developments relevant to primary care

Management of bipolar disorder: developments relevant to primary care Primary Care Mental Health 2006;4:00 00 # 2006 Radcliffe Publishing International research Management of bipolar disorder: developments relevant to primary care André Tylee Professor of Primary Care Mental

More information

Algorithm for Initiating Antidepressant Therapy in Depression

Algorithm for Initiating Antidepressant Therapy in Depression Algorithm for Initiating Antidepressant Therapy in Depression Refer for psychotherapy if patient preference or add cognitive behavioural office skills to antidepressant medication Moderate to Severe depression

More information

The role of psychoeducation in the complex treatment of bipolar disorder

The role of psychoeducation in the complex treatment of bipolar disorder The role of psychoeducation in the complex treatment of bipolar disorder Bartosz Grabski, Grzegorz Mączka, Dominika Dudek Summary The importance of psychosocial interventions in bipolar disorder has recently

More information

Symptoms of mania can include: 3

Symptoms of mania can include: 3 Bipolar Disorder This factsheet gives information on bipolar disorder. It explains the symptoms of bipolar disorder, treatments and ways to manage symptoms. It also covers what treatment the National Institute

More information

Clinical overview. R. W. Licht 1, H. Gijsman 2, W. A. Nolen 3, J. Angst 4 1 Mood Disorders Research Unit, Aarhus University

Clinical overview. R. W. Licht 1, H. Gijsman 2, W. A. Nolen 3, J. Angst 4 1 Mood Disorders Research Unit, Aarhus University Acta Psychiatr Scand 2008: 118: 337 346 All rights reserved DOI: 10.1111/j.1600-0447.2008.01237.x Copyright Ó 2008 The Authors Journal Compilation Ó 2008 Blackwell Munksgaard ACTA PSYCHIATRICA SCANDINAVICA

More information

DEMENTIA EDUCATION & TRAINING PROGRAM

DEMENTIA EDUCATION & TRAINING PROGRAM The pharmacological management of aggression in the nursing home requires careful assessment and methodical treatment to assure maximum safety for patients, nursing home residents and staff. Aggressive

More information

FACT SHEET 4. Bipolar Disorder. What Is Bipolar Disorder?

FACT SHEET 4. Bipolar Disorder. What Is Bipolar Disorder? FACT SHEET 4 What Is? Bipolar disorder, also known as manic depression, affects about 1 percent of the general population. Bipolar disorder is a psychiatric disorder that causes extreme mood swings that

More information

COUNTY OF LOS ANGELES - DEPARTMENT OF MENTAL HEALTH OFFICE OF THE MEDICAL DIRECTOR. 3.4 PARAMETERS FOR THE USE OF ANXIOLYTIC MEDICATIONS October 2014

COUNTY OF LOS ANGELES - DEPARTMENT OF MENTAL HEALTH OFFICE OF THE MEDICAL DIRECTOR. 3.4 PARAMETERS FOR THE USE OF ANXIOLYTIC MEDICATIONS October 2014 COUNTY OF LOS ANGELES - DEPARTMENT OF MENTAL HEALTH OFFICE OF THE MEDICAL DIRECTOR 3.4 PARAMETERS FOR THE USE OF ANXIOLYTIC MEDICATIONS October 2014 I. GENERAL CONSIDERATIONS A. Definition: Anxiolytic

More information

Treatment of Patients With Bipolar Disorder Second Edition

Treatment of Patients With Bipolar Disorder Second Edition PRACTICE GUIDELINE FOR THE Treatment of Patients With Bipolar Disorder Second Edition WORK GROUP ON BIPOLAR DISORDER Robert M.A. Hirschfeld, M.D., Chair Charles L. Bowden, M.D. Michael J. Gitlin, M.D.

More information

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic. bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.

More information

Understanding mania and hypomania

Understanding mania and hypomania Understanding mania and hypomania 1 Contents What are mania and hypomania? 3 How are mania and hypomania diagnosed? 4 What causes mania and hypomania? 5 What treatments are available? 5 How can I help

More information

Efficacy and safety of antidepressants use in the treatment of depressive episodes in bipolar disorder review of research

Efficacy and safety of antidepressants use in the treatment of depressive episodes in bipolar disorder review of research Psychiatr. Pol. 2015; 49(6): 1223 1239 PL ISSN 0033-2674 (PRINT), ISSN 2391-5854 (ONLINE) www.psychiatriapolska.pl DOI: http://dx.doi.org/10.12740/pp/37914 Efficacy and safety of antidepressants use in

More information

American Psychiatric Association

American Psychiatric Association Practice Guideline for the Treatment of Patients With Bipolar Disorder (Revision) American Psychiatric Association Originally published in April 2002. A guideline watch, summarizing significant developments

More information

Frequently Asked Questions About Prescription Opioids

Frequently Asked Questions About Prescription Opioids Mental Health Consequences of Prescription Drug Addictions Opioids, Hypnotics and Benzodiazepines Learning Objectives 1. To review epidemiological data on prescription drug use disorders Ayal Schaffer,

More information

Big data size isn t enough! Irene Petersen, PhD Primary Care & Population Health

Big data size isn t enough! Irene Petersen, PhD Primary Care & Population Health Big data size isn t enough! Irene Petersen, PhD Primary Care & Population Health Introduction Reader (Statistics and Epidemiology) Research team epidemiologists/statisticians/phd students Primary care

More information

Steven Bander, DO, FACOFP Bander Family Medical Center Wylie, Texas

Steven Bander, DO, FACOFP Bander Family Medical Center Wylie, Texas Bipolar Disorder: Lessons for Rural Physicians: Adjunctive Interventions for Maintaining Remission Steven Bander, DO, FACOFP Bander Family Medical Center Wylie, Texas Disclosure Nothing to disclose Objectives

More information

MOLINA HEALTHCARE OF CALIFORNIA

MOLINA HEALTHCARE OF CALIFORNIA MOLINA HEALTHCARE OF CALIFORNIA MAJOR DEPRESSION IN ADULTS IN PRIMARY CARE HEALTH CARE GUIDELINE (ICSI) Health Care Guideline Twelfth Edition May 2009. The guideline was reviewed and adopted by the Molina

More information

Trends in Prescribing of Antipsychotic Drugs in General Practice in England (Chart 1) 2.0. Other second generation antipsychotics (SGA)

Trends in Prescribing of Antipsychotic Drugs in General Practice in England (Chart 1) 2.0. Other second generation antipsychotics (SGA) Antipsychotic drugs Antipsychotics can be broadly classified into first generation antipsychotics (FGAs, formerly known as typical antipsychotics) and second generation antipsychotics (SGAs, formerly known

More information

TEXAS MEDICATION ALGORITHM PROJECT PROCEDURAL MANUAL

TEXAS MEDICATION ALGORITHM PROJECT PROCEDURAL MANUAL TEXAS MEDICATION ALGORITHM PROJECT PROCEDURAL MANUAL BIPOLAR DISORDER ALGORITHMS M. Lynn Crismon, PharmD, BCPP Tami R. Argo, PharmD, MS, BCPP Sherrie D. Bendele, BS Trisha Suppes, MD, PhD 2007, Texas Department

More information

B i p o l a r D i s o r d e r

B i p o l a r D i s o r d e r B i p o l a r D i s o r d e r Professor Ian Jones Director National Centre for Mental Health www.ncmh.info @ncmh_wales /WalesMentalHealth 029 2074 4392 info@ncmh.info Robert Schumann 1810-1856 Schumann's

More information

Widow with clear history of recurrent depressions and hypomanias. Previously well-maintained on lithium.

Widow with clear history of recurrent depressions and hypomanias. Previously well-maintained on lithium. W. Vaughn McCall, MD, MS Chart Review: ECT PATIENT INFO 73 Age: Female Sex: Widow with clear history of recurrent depressions and hypomanias. Previously well-maintained on lithium. Background: History

More information

Anew understanding of the symptoms

Anew understanding of the symptoms An Overview of Primary Care Assessment and Management of Bipolar Disorder Frederick T. Lewis, DO Ethan Kass, DO, MBA Robert M. Klein, DO Because patients with major psychiatric illnesses increasingly are

More information

Bipolar Disorder Practice Guidelines for Adults

Bipolar Disorder Practice Guidelines for Adults Bipolar Disorder Practice Guidelines for Adults Introduction PerformCare s condensed guidelines for the treatment of Bipolar Disorder are derived from the American Psychiatric Association (APA) Guidelines

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS IN THE TREATMENT OF DEPRESSION

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS IN THE TREATMENT OF DEPRESSION The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 25 April 2002 CPMP/EWP/518/97, Rev. 1 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE

More information

New Treatments. For Bipolar Disorder. Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine

New Treatments. For Bipolar Disorder. Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine New Treatments For Bipolar Disorder Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine Abbott Laboratories AstraZeneca Bristol-Myers Squibb Corcept

More information

Bipolar Disorder: Advances in Psychotherapy

Bipolar Disorder: Advances in Psychotherapy Bipolar Disorder: Advances in Psychotherapy Questions from chapter 1 1) Which is characterized by one or more major depressive episodes with at least one hypomanic episode in which the patient s functioning

More information

Bipolar Disorder: Psychosocial Factors and Psychological Therapies. Steve Jones Spectrum Centre for Mental Health Research

Bipolar Disorder: Psychosocial Factors and Psychological Therapies. Steve Jones Spectrum Centre for Mental Health Research Bipolar Disorder: Psychosocial Factors and Psychological Therapies Steve Jones Spectrum Centre for Mental Health Research Overview Scale of the Problem Factors associated with Bipolar course and outcome

More information

Lithium in bipolar and other affective disorders: prescribing practice in the UK

Lithium in bipolar and other affective disorders: prescribing practice in the UK Original Paper Lithium in bipolar and other affective disorders: prescribing practice in the UK Carol Paton 1,2, Thomas RE Barnes 1,2, Amber Shingleton-Smith 2, R Hamish McAllister-Williams 3, James Kirkbride

More information

Prepared by:jane Healey (Email: janie_healey@yahoo.com) 4 th year undergraduate occupational therapy student, University of Western Sydney

Prepared by:jane Healey (Email: janie_healey@yahoo.com) 4 th year undergraduate occupational therapy student, University of Western Sydney 1 There is fair (2b) level evidence that living skills training is effective at improving independence in food preparation, money management, personal possessions, and efficacy, in adults with persistent

More information

Robert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy

Robert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy Robert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy Judith Long, MD,RWJCS Perelman School of Medicine Philadelphia Veteran Affairs Medical Center Background Objective Overview Methods

More information

Antipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease

Antipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease Antipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease Professional Tool #1: Screening and Monitoring in a High-Risk Population: Questions and Answers Overview of Cardiometabolic

More information

Borderline personality disorder

Borderline personality disorder Borderline personality disorder Treatment and management Issued: January 2009 NICE clinical guideline 78 guidance.nice.org.uk/cg78 NICE 2009 Contents Introduction... 3 Person-centred care... 5 Key priorities

More information

The submission positioned dimethyl fumarate as a first-line treatment option.

The submission positioned dimethyl fumarate as a first-line treatment option. Product: Dimethyl Fumarate, capsules, 120 mg and 240 mg, Tecfidera Sponsor: Biogen Idec Australia Pty Ltd Date of PBAC Consideration: July 2013 1. Purpose of Application The major submission sought an

More information

National Depressive and Manic-Depressive Association Constituency Survey

National Depressive and Manic-Depressive Association Constituency Survey Living with Bipolar Disorder: How Far Have We Really Come? National Depressive and Manic-Depressive Association Constituency Survey 2001 National Depressive and Manic-Depressive Association National Depressive

More information

The Quality Concern: Behavioral Health Inpatient Readmissions

The Quality Concern: Behavioral Health Inpatient Readmissions The Readmissions Quality Collaborative Kick-Off Conference June 21, 2012 The Quality Concern: Behavioral Health Inpatient Readmissions Molly Finnerty, MD Director, Bureau of Evidence Based Services and

More information

MEDICAL POLICY No. 91608-R1 MENTAL HEALTH RESIDENTIAL TREATMENT: ADULT

MEDICAL POLICY No. 91608-R1 MENTAL HEALTH RESIDENTIAL TREATMENT: ADULT MENTAL HEALTH RESIDENTIAL TREATMENT: ADULT Effective Date: June 4, 2015 Review Dates: 5/14, 5/15 Date Of Origin: May 12, 2014 Status: Current Summary of Changes Clarifications: Pg 4, Description, updated

More information

TREATING ASPD IN THE COMMUNITY: FURTHERING THE PD OFFENDER STRATEGY. Jessica Yakeley Portman Clinic Tavistock and Portman NHS Foundation Trust

TREATING ASPD IN THE COMMUNITY: FURTHERING THE PD OFFENDER STRATEGY. Jessica Yakeley Portman Clinic Tavistock and Portman NHS Foundation Trust TREATING ASPD IN THE COMMUNITY: FURTHERING THE PD OFFENDER STRATEGY Jessica Yakeley Portman Clinic Tavistock and Portman NHS Foundation Trust Treating the untreatable? Lack of evidence base for ASPD Only

More information

Bipolar Disorders. Poll Question

Bipolar Disorders. Poll Question Bipolar Disorders American Counseling Association DSM-V Webinar Series July 10, 2013 Dr. Todd F. Lewis, Ph.D., LPC, NCC The University of North Carolina at Greensboro Poll Question Who are you? Clinical

More information

Comorbid Conditions in Autism Spectrum Illness. David Ermer MD June 13, 2014

Comorbid Conditions in Autism Spectrum Illness. David Ermer MD June 13, 2014 Comorbid Conditions in Autism Spectrum Illness David Ermer MD June 13, 2014 Overview Diagnosing comorbidities in autism spectrum illnesses Treatment issues specific to autism spectrum illnesses Treatment

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare

More information

TREATING BIPOLAR DISORDER

TREATING BIPOLAR DISORDER TREATING BIPOLAR DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Bipolar Disorder, Second Edition, originally published in April 2002. 1 For Continuing Medical

More information

Psychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI

Psychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT

More information

Antidepressants and suicidal thoughts and behaviour. Pharmacovigilance Working Party. January 2008

Antidepressants and suicidal thoughts and behaviour. Pharmacovigilance Working Party. January 2008 Antidepressants and suicidal thoughts and behaviour Pharmacovigilance Working Party January 2008 PhVWP PAR January 2008 Page 1/15 1. Introduction The Pharmacovigilance Working Party has on a number of

More information

in young people Management of depression in primary care Key recommendations: 1 Management

in young people Management of depression in primary care Key recommendations: 1 Management Management of depression in young people in primary care Key recommendations: 1 Management A young person with mild or moderate depression should typically be managed within primary care services A strength-based

More information

CARE MANAGEMENT FOR LATE LIFE DEPRESSION IN URBAN CHINESE PRIMARY CARE CLINICS

CARE MANAGEMENT FOR LATE LIFE DEPRESSION IN URBAN CHINESE PRIMARY CARE CLINICS CARE MANAGEMENT FOR LATE LIFE DEPRESSION IN URBAN CHINESE PRIMARY CARE CLINICS Dept of Public Health Sciences February 6, 2015 Yeates Conwell, MD Dept of Psychiatry, University of Rochester Shulin Chen,

More information

BEST in MH clinical question-answering service

BEST in MH clinical question-answering service Best Evidence Summaries of Topics in Mental Healthcare BEST in MH clinical question-answering service Question In adults with a diagnosis of psychotic / delusional depression how effective is electroconvulsive

More information

Antipsychotic drugs are the cornerstone of treatment

Antipsychotic drugs are the cornerstone of treatment Article Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic T. Scott Stroup, M.D.,

More information

Treatment Interventions for Suicide Prevention. Kate Comtois, PhD, MPH University of Washington

Treatment Interventions for Suicide Prevention. Kate Comtois, PhD, MPH University of Washington Treatment Interventions for Suicide Prevention Kate Comtois, PhD, MPH University of Washington Suicide prevention has many forms Treating Depression Gatekeeper Training Public health or injury prevention

More information

TREATMENT-RESISTANT DEPRESSION AND ANXIETY

TREATMENT-RESISTANT DEPRESSION AND ANXIETY University of Washington 2012 TREATMENT-RESISTANT DEPRESSION AND ANXIETY Catherine Howe, MD, PhD University of Washington School of Medicine Definition of treatment resistance Failure to remit after 2

More information

Practice guideline for the treatment of patients with bipolar disorder (revision).

Practice guideline for the treatment of patients with bipolar disorder (revision). Brief Summary GUIDELINE TITLE Practice guideline for the treatment of patients with bipolar disorder (revision). BIBLIOGRAPHIC SOURCE(S) Practice guideline for the treatment of patients with bipolar disorder

More information

Antiepileptics and suicidal thoughts and behaviour. Pharmacovigilance Working Party. June 2008

Antiepileptics and suicidal thoughts and behaviour. Pharmacovigilance Working Party. June 2008 Antiepileptics and suicidal thoughts and behaviour Pharmacovigilance Working Party June 2008 PhVWP AED PAR 0608 1 1.0 The Issue Over the last few years concerns have arisen about the risk of suicidal thoughts

More information

Is Your Depressed Patient Bipolar? Supported by an unrestricted grant from GlaxoSmithKline, Inc.

Is Your Depressed Patient Bipolar? Supported by an unrestricted grant from GlaxoSmithKline, Inc. Is Your Depressed Patient Bipolar? Running foot: Is Your Depressed Patient Bipolar? Acknowledgments Supported by an unrestricted grant from GlaxoSmithKline, Inc. Keywords: bipolar disorders, bipolar II,

More information

Medication Treatment of Bipolar Disorder 2000

Medication Treatment of Bipolar Disorder 2000 The Expert Consensus Guideline Series Medication Treatment of Bipolar Disorder 2000 Gary S. Sachs, M.D. Director of Partners Bipolar Treatment Center, Massachusetts General Hospital Assistant Professor

More information

The management of bipolar disorder in adults, children and adolescents, in primary and secondary care

The management of bipolar disorder in adults, children and adolescents, in primary and secondary care Quick reference guide Issue date: July 2006 Bipolar disorder The management of bipolar disorder in adults, children and adolescents, in primary and secondary care Developed by the National Collaborating

More information

Update on guidelines on biological treatment of depressive disorder. Dr. Henry CHEUNG Psychiatrist in private practice

Update on guidelines on biological treatment of depressive disorder. Dr. Henry CHEUNG Psychiatrist in private practice Update on guidelines on biological treatment of depressive disorder Dr. Henry CHEUNG Psychiatrist in private practice 2013 update International Task Force of World Federation of Societies of Biological

More information

COMPREHENSIVE MANAGEMENT OF THE ELDERLY PATIENT WITH MANIA

COMPREHENSIVE MANAGEMENT OF THE ELDERLY PATIENT WITH MANIA COMPREHENSIVE MANAGEMENT OF THE ELDERLY PATIENT WITH MANIA Manic depressive illness is a biological brain disorder that produces significant alterations of mood and psychosis. Mania in the elderly occurs

More information

Evidence-based guidelines for treating bipolar disorder: revised second edition recommendations from the British Association for Psychopharmacology

Evidence-based guidelines for treating bipolar disorder: revised second edition recommendations from the British Association for Psychopharmacology BAP Guidelines Evidence-based guidelines for treating bipolar disorder: revised second edition recommendations from the British Association for Psychopharmacology Journal of Psychopharmacology 23(4) (2009)

More information